STOCK TITAN

Aligos extends South SF HQ lease to 2034

(High)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Aligos Therapeutics, Inc. (ALGS) entered into a First Amendment to its headquarters lease in South San Francisco with Britannia Biotech Gateway Limited Partnership, extending the lease term from March 31, 2027 to March 31, 2034 and updating rent and flexibility terms.

The amendment sets base monthly rent per rentable square foot at $4.650 from April 1, 2027, escalating annually to $5.716 from April 1, 2033 to March 31, 2034, and requires Aligos to pay a specified percentage of certain landlord expenses. Aligos receives a 10‑month rent abatement from April 1, 2027 to January 31, 2028, subject to no material default. The company gains a one-time option to terminate the lease as of March 31, 2031 by giving notice by March 31, 2030 and paying $2,476,429.22 in termination consideration, plus a separate right to terminate without penalty if it signs a qualifying new lease of at least 60,000 rentable square feet with the landlord or its affiliate. The existing extension option is revised to one seven‑year option following the extended term.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Extended lease end date March 31, 2034 New expiration of headquarters lease term after First Amendment
Base rent per square foot (2027–2028) $4.650 per rentable square foot per month From April 1, 2027 to March 31, 2028
Base rent per square foot (2033–2034) $5.716 per rentable square foot per month From April 1, 2033 to March 31, 2034
Rent abatement period 10 months From April 1, 2027 to January 31, 2028, subject to no material default
Termination consideration $2,476,429.22 Amount payable if Aligos terminates lease effective March 31, 2031 under one-time option
Minimum space for penalty-free new lease 60,000 rentable square feet Required size of new lease to use penalty-free termination right
Revised extension option length 7 years One seven-year extension option following the extended term
Material Definitive Agreement regulatory
"Item 1.01 Entry into a Material Definitive Agreement"
A material definitive agreement is a legally binding contract that creates major, long‑term obligations or rights for a company, such as loans, asset sales, mergers, or supplier deals. Think of it like a mortgage or lease for a business: it can change future cash flow, risk and control, so investors watch these agreements closely because they can materially affect a company’s value, financial health and stock price.
rent abatement financial
"The Company will also be granted a rent abatement for ten months"
A temporary reduction or suspension of rent a tenant must pay, negotiated into a lease or granted by a landlord for a set period or specific circumstances. It matters to investors because it directly changes a property owner’s rental income and cash flow—like a short-term discount or payment pause—and can affect valuation, debt coverage, and a tenant’s ability to stay in place during repairs, fit-outs, or financial strain.
termination consideration financial
"payment on or before the termination date of $2,476,429.22 in termination consideration"
extension option financial
"The First Amendment revises the existing extension option under the Lease"
rentable square feet financial
"covering no less than 60,000 rentable square feet"
Rentable square feet is the total floor area a landlord charges tenants for, including the tenant’s usable space plus a proportional share of common areas like lobbies, hallways and restrooms. Investors use it to calculate income and compare properties because rent and lease rates are typically quoted per rentable square foot; think of it as the full ticket price that includes your seat plus a share of the theater’s aisles and lobby.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What lease change did Aligos Therapeutics (ALGS) announce on September 10, 2026?

Aligos Therapeutics entered into a First Amendment to its headquarters lease, extending the term from March 31, 2027 to March 31, 2034, and revising rent, expense-sharing, termination options, and the future extension option.

How do base rents change under the new Aligos (ALGS) lease amendment?

Base monthly rent per rentable square foot is $4.650 from April 1, 2027 to March 31, 2028, then increases annually, reaching $5.716 from April 1, 2033 to March 31, 2034, as specified in the amendment.

Does Aligos Therapeutics (ALGS) receive any rent abatement under the amended lease?

Yes. Aligos receives a ten‑month rent abatement from April 1, 2027 to January 31, 2028, provided there is no material default under the lease during that period.

What early termination right does Aligos (ALGS) have in the lease amendment?

Aligos has a one-time option to terminate the lease as of March 31, 2031, if it gives written notice on or before March 31, 2030 and pays $2,476,429.22 in termination consideration by the termination date.

What is the penalty-free termination option described for Aligos (ALGS)?

Aligos may terminate the lease without penalty on at least 30 days’ written notice if it and the landlord or an affiliate fully execute a new lease in the same or another owned project, extending beyond the then-latest lease expiration and covering at least 60,000 rentable square feet.

How was the extension option under the Aligos (ALGS) lease revised?

The existing extension option was changed from one eight‑year option to one seven‑year option, exercisable by written notice for the seven‑year period immediately following the expiration of the extended term ending March 31, 2034.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
false 0001799448 0001799448 2026-09-10 2026-09-10
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 10, 2026

 

 

Aligos Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-39617   82-4724808

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

One Corporate Dr., 2nd Floor  
South San Francisco, CA   94080
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (800) 466-6059

(Former Name or Former Address, if Changed Since Last Report): N/A

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share   ALGS   The Nasdaq Stock Market LLC
    (Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 1.01 Entry into a Material Definitive Agreement.

On September 10, 2026, Aligos Therapeutics, Inc. (the “Company”) entered into the First Amendment to Lease (the “First Amendment”) with Britannia Biotech Gateway Limited Partnership (the “Landlord”), to amend the Lease, dated as of June 21, 2018, by and between the Landlord and the Company (as amended, the “Lease”), relating to office space located at One Corporate Drive, 2nd Floor, South San Francisco, CA 94080, which serves as the Company’s headquarters. The First Amendment extends the term of the Lease from March 31, 2027 to March 31, 2034. The First Amendment provides that the base monthly rent, per rentable square foot of the leased space, will be $4.650 from April 1, 2027 to March 31, 2028, $4.813 from April 1, 2028 to March 31, 2029, $4.981 from April 1, 2029 to March 31, 2030, $5.156 from April 1, 2030 to March 31, 2031, $5.336 from April 1, 2031 to March 31, 2032, $5.523 from April 1, 2032 to March 31, 2033, and $5.716 from April 1, 2033 to March 31, 2034, and that the Company will be obligated to pay a specified percentage of certain expenses paid by the Landlord. The Company will also be granted a rent abatement for ten months from April 1, 2027 to January 31, 2028, provided there is no material default under the Lease.

The First Amendment also grants the Company (a) a one-time option to terminate the Lease as of March 31, 2031 upon written notice delivered on or before March 31, 2030 and payment on or before the termination date of $2,476,429.22 in termination consideration and (b) the right to terminate the Lease without payment of any penalty or termination fee upon not less than 30 days’ prior written notice if the Company and the Landlord or an affiliate of the Landlord fully execute and deliver a new lease for other space in the Project (as defined therein) or in a project owned by the Landlord or an affiliate of the Landlord, with a term extending beyond the then-latest expiration date of the Lease and covering no less than 60,000 rentable square feet.

The First Amendment revises the existing extension option under the Lease from one (1) eight (8) year option to one (1) seven (7) year option, exercisable upon written notice, for the seven year period immediately following the expiration of the extended term.

The foregoing description of the First Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the First Amendment, which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2026.

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ALIGOS THERAPEUTICS, INC.
Date: September 15, 2026     By:  

/s/ Lesley Ann Calhoun

    Name:   Lesley Ann Calhoun
    Title:   Executive Vice President, Chief Operating
      Officer & Chief Financial Officer

Filing Exhibits & Attachments

3 documents

Keep reading